MarinHealth Medical Center (MHMC) announced today that its surgeons have performed the first Aquablation procedures to treat ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Anticipated growth for ‘Saudi Arabia Benign Prostatic Hyperplasia Treatment Market’ is significant from 2024 to 2032. The market showed steady growth in 2024 and is expected to continue rising due to ...

VIJAYAWADA: Prashanth Hospital in Vijayawada introduced Resume Water Vapour Therapy for prostate problems, a first in the ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

Alfuzosin alone and alfuzosin-finasteride combination therapy significantly improved symptoms when compared with finasteride alone, as assessed with the International Prostate Symptom Score.

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

The treatment of benign prostatic hyperplasia (BPH) that causes lower urinary tract symptoms has advanced enormously since the days when it was a simple choice between no treatment with ...

Benign prostatic hyperplasia (BPH), also called prostate gland enlargement, is a common condition that older men can suffer ...

As with any new supplement, it's crucial to consult a healthcare provider before starting ProstaVive, particularly if you have pre-existing conditions, are on other medications, or are undergoing ...

An announcement from Nymox Pharmaceutical ( (NYMXF) ) is now available.